Vedder

Vedder Bio is a biotechnology company focused on developing therapeutics to reverse tissue stiffening and other pathologies associated with aging. The company specifically targets Advanced Glycation End-products (AGEs), such as glucosepane, which form irreversible crosslinks in the extracellular matrix over time. By developing AGE-breakers, Vedder Bio aims to restore the elasticity and function of tissues in the cardiovascular system, kidneys, and skin. The company's research is based on pioneering work from the Spiegel Lab at Yale University, which achieved the first total synthesis of glucosepane. This breakthrough allows for the high-throughput screening and development of molecules capable of breaking these specific bonds. Vedder Bio operates as a portfolio company of Kizoo Technology Capital, contributing to the growing field of rejuvenation biotechnology.